Results 1 to 10 of about 18,836 (198)

Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India

open access: yesInternational Journal of Infectious Diseases, 2022
Objectives: Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. The delayed release (DR) tablet of posaconazole has been shown to have a superior pharmacokinetic profile in comparison with the ...
Parikshit S. Prayag   +8 more
doaj   +1 more source

THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

open access: yesМедицинский совет, 2017
Efficacy of posaconazole for prophylaxis was evaluated in 77 chemotherapy cycles in 59 patients with acute myeloid leukemia (AML) aged 39 (17–62) years from 2012  till 2017.
G. A. Klyasova   +5 more
doaj   +1 more source

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients

open access: yesBlood Science, 2023
Invasive fungal diseases (IFDs) are major and lethal infectious complications for patients with neutropenia after chemotherapy. Prophylaxis with intravenous and oral suspended itraconazole (200 mg Q12h intravenously × 2 days followed by 5 mg/kg·d orally ...
Li Liu   +12 more
doaj   +1 more source

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

open access: yesAnnals of Clinical Microbiology and Antimicrobials, 2017
Background Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of posaconazole and voriconazole pharmacokinetic variability. However, its benefits on clinical outcomes are still being defined.
Whitley M. Yi   +6 more
doaj   +1 more source

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

open access: yesTurkish Journal of Hematology, 2018
Objective: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation.
Vildan Özkocaman   +9 more
doaj   +1 more source

Posaconazole treatment of refractory coccidioidomycosis in dogs

open access: yesJournal of Veterinary Internal Medicine, 2021
Background The majority of dogs with coccidioidomycosis recover with administration of fluconazole or itraconazole, although some cases are refractory or the dogs do not tolerate administration of these medications.
Lisa F. Shubitz   +4 more
doaj   +1 more source

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf

open access: yesMedical Mycology Case Reports, 2021
Mucorales infections in cetaceans have a high mortality rate. This case report refers to a bottlenose dolphin calf with suspected mucormycosis treated with posaconazole.
Gonçalo N. Marques   +3 more
doaj   +1 more source

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole

open access: yesEcho Research and Practice, 2018
We describe severe hypokalaemia and hypertension due to a mineralocorticoid effect in a patient with myelodysplastic syndrome taking posaconazole as antifungal prophylaxis.
Charlotte Boughton   +4 more
doaj   +1 more source

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2017
Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications ...
Mayur D. Mody MD   +3 more
doaj   +1 more source

Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis

open access: yesBMC Infectious Diseases, 2018
Background Posaconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of posaconazole TDM and the target of posaconazole plasma concentration for clinical successful prophylaxis remain uncertain and ...
Lu Chen   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy